GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential

Funding Acknowledgements

JA Hamilton is employed by The University of Melbourne. The University of Melbourne has licensed patented technology relating to therapeutically targeting GM-CSF to MorphoSys AG, Germany. JA Hamilton has consultancies with GSK and CSL Pty Ltd amounting to less than

0,000 per year per entity. This work was supported by a Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia. Rifa Sallay is acknowledged for typing the manuscript. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.